A B S T R A C T Serum disappearance curves in dogs after the intravenous injection of radioactive methotrexate, 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, and folic acid followed first-order kinetics with half-disappearance times ranging from 1.3 to 9 hr respectively. Equilibration of spinal fluid tritium levels with those in serum was rapid (3.0 hr) for both of the reduced folates but was not observed at any time after folic acid and methotrexate. The only radioactive folate identified in the spinal fluid after intravenous injection of either 5-formyltetrahydrofolate or folic acid, as well as 5-methyltetrahydrofolate was 5-methyltetrahydrofolate. These findings indicated that 5-methyltetrahydrofolate was taken up preferentially into the spinal fluid and that the other folate congeners were converted to this compound before uptake. Diphenylhydantoin administration did not alter the uptake of 5-methyltetrahydrofolate into the spinal fluid but was associated with reduced renal excretion of this compound.
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vivo. The observation of higher concentrations of MeFHi -in the cerebrospinal fluid (CSF) than in serum (2) (3) (4) (5) , the selective conservation of folates in the central nervous system (6) , and the association of neuropsychiatric disorders with disturbances of folate metabolism (7) (8) (9) suggest that folate coenzymes play an important role in neural metabolism. The association of mental retardation, cerebral calcification, and megaloblastic anemia with combined defects in gastrointestinal and CSF transport of folates has been reported (10) . The low concentration of vitamin B12 (11) in CSF suggests that the BuaMeFH4 transmethylase is not essential to neural folate metabolism. The relatively constant ratio between serum and CSF folate concentrations observed in individual patients (4, 5) suggests the existence of a homeostatic mechanism for the maintenance of CSF folate concentration, perhaps involving a transport function at the "blood-brain barrier."
Past studies of folate transport have been hampered by the limitations of microbiologic assays or have employed tritiated folic acid (FA), which is unphysiologic, rather than MeFH4. In the present study, radiochemically pure, doubly labeled 5-methyl-14C-tetrahydrofolate-9,3',5'-'H (Me*FH*4) and 5-formyl-"4C-tetrahydrofolate-9,3',5'-'H (Me*FH*4) were utilized to compare the metabolic disposition of these folate coenzyme with that of FA-9,3',5'-3H (FA*) and methotrexate-9,3',5'-3H (MTX*).
Diphenylhydantoin (DPH) has been implicated as an etiologic agent in cases of megaloblastic anemia which have responded to folate therapy (12) . More recently it has been suggested that some cases of dementia in epileptics may result from a DPH-dependent lowering of folate levels in both serum and CSF (7) . Since Woodbury and Kemp (16) demonstrated decreased FA* uptake into the CSF after DPH, it was of interest to determine the effect of DPH treatment upon the transport of Me*FH*& between the CSF and blood. (13) . In brief, FA* was chemically reduced to dihydrofolate, then enzymatically reduced to FH4 in the presence of formaldehyde-"4C, which resulted in the formation of 5,10-methylene-'4C-FH4-'H. This material was either reduced with KBH4 to prepare Me*FH*4, or the enzyme 5,10-methyleneFH4 dehydrogenase was used to produce 5, 10-methenyl-'4C-FH4-'H; when autoclaved at neutral pH in the presence of ascorbate, this latter was converted to f*FH*4. In both cases the products were purified by ionexchange chromatography on DEAE-Sephadex and gel filtration on Sephadex G15. The final product was more than 99% radiochemically pure in the case of f*FH*4 and more than 95%o radiochemically pure in the case of Me*-FH*4 as assessed by chromatography in three systems.
METHODS
General procedures. Mongrel dogs of either sex weighing 10-20 kg were anesthetized with intravenous sodium pentobarbital, 30 mg/kg. Urine To measure the efflux kinetics of Me*FH*4 from the CSF in both control and DPH-treated dogs, four animals were utilized. An intracisternal injection of 25 pig/kg of Me*-FH*4 in 0.4 ml 0.9% saline was carried out over a period of 5 min in each of the four animals. Blood samples and in some cases urine samples were obtained at intervals. Two of the dogs received no DPH; the third dog was given 10 mg/kg and the fourth 30 mg/kg of DPH i.v. 1 hr before radioisotope injection.
Scintillation counting. Serum specimens were prepared for counting as follows: 2.0-ml portions of serum were deproteinized by the addition of 0.5 ml 10% perchloric acid. After centrifugation at 3500 rpm for 15 min, 0.5 ml of each supernatant was placed in a glass counting vial with 20 ml of scintillation fluid. The latter consisted of two parts of toluene containing 4 g PPO (2,5-diphenyloxazole) plus 50 mg POPOP (1,4-bis [2-(5-phenyloxazolyl) ]-benzene) per liter and one part of 100% ethanol. Portions of 0.5 ml of CSF and urine were counted directly in 20 ml of the same scintillation fluid. When low levels of radioactivity were expected, Aquafluor scintillation mixture (1 ml sample to 10 ml of Aquafluor) was employed.
For counting of 'H and of 14C in samples containing both radioisotopes, four channels of the liquid scintillation spectrometer were utilized. In two channels, external standards were counted and expressed as a channels ratio. One channel was set so as to optimize "C counting in the quenched samples while excluding 'H. The fourth channel was set to both optimize 'H counting and minimize "C counting in the quenched samples. The spillover of 14C into the 'H channel and the efficiency of counting of each isotope were determined from a calibration chart constructed with reference to the external standard channels ratio (14) .
Spinal fluid chromatography. Identification of the radiolabels in CSF was determined by the method of Nixon and Bertino (15) . To 10-20 ml of labeled CSF was added 2 /Amoles of p-aminobenzoylglutamate (p-ABG) and 2 ,moles of unlabeled MeFH4. The material was then applied to a column of A-25 DEAE-Sephadex equilibrated with 0.1 M potassium phosphate buffer at pH 6 containing 10 mm 2-mercaptoethanol. Elution was carried out by means of a linear concentration gradient constructed by placing 250 ml of 0.1 M phosphate buffer in the mixing chamber and 250 ml of 0.8 M phosphate buffer in the reservoir. Fractions of 2.5 ml each were collected and monitored for radioactivity. Fluorometry or UV-absorbence spectrometry was carried out over the range 240-350 m~u to establish the identity of marker compounds. Radioactivity was determined by counting 1 ml of each fraction in 10 ml of Aquafluor scintillation fluid on a liquid scintillation spectrometer using the double label corrections where appropriate. RESULTS With one exception, the results presented are those from a single experiment which is representative of almost identical replicate experiments. In the case of the data shown in Fig. 3 , the results of duplicate experiments have been included since they were not entirely consistent.
Uptake of folate congeners into spinal fluid. The serum disappearance and spinal fluid uptake data after intravenous injection of either Me*FH*4, f*FH*4, FA*, or MTX* are shown in Fig. 1 and Table I . With the reduced compounds the serum isotope disappearance curves for all four compounds were parallel and consistent with a biphasic (A and B) first-order disappearance rate plot. Phase A of serum disappearance (Table I ) appeared to be complete before the appearance of measurable amounts of radioactivity in CSF (Fig. 1) . Equilibration of CSF tritium levels with those in serum was rapid for both Me*FH*4 and f*FH*4 at 3.0 hr, but was not observed at any time after FA* or MTX*. The CSF: serum-14C equilibration rate after f*FH*4 was significantly more rapid than that of tritium. CSF: blood equilibration was observed at the following serum isotope concentrations: Me*FH*4 2.5% (of injected radioactivity per liter) ; f*FH*4, 1%.
Diphenyihydantoin. Pretreatment of dogs with DPH (cf. experimental) resulted in serum disappearance and CSF uptake curves after i.v. Me*FH*4 which were indistinguishable from those in untreated animals (Fig. 2 , Table I ).
The maximum serum levels observed after intrathecal injection of Me*FH*4 were 4.0-5.1% of the injected radioactivity per liter in two control dogs and 6.3-7.8% in two DPH-pretreated dogs (Fig. 3) . The data for serum appearance of radiolabels differed within both the control and the pretreated animals pairs (Fig. 3) . (Fig. 4) . Coincident elution of radioisotopes with the unlabeled MeFH4 "marker" was interpreted as indicating chemical coidentity. By this criterion Me*FH*4 was found in the spinal fluid after intravenous injection of all of the three labeled folates. All three of the spinal fluids contained variable amounts of radioactivity other than Me*FH*4. The early eluting material was probably not in the form of folates and may have been amino acids, formaldehyde, methionine, pteridines, and PABG. This is discussed below. These findings indicated that whatever the identity of folates in the blood, their appearance in CSF was dependent upon conversion to Me*FH*4. DISCUSSION Several striking characteristics of serum: CSF folate transport have been observed in this study. The pre- Fig. 1 ), the CSF: serum isotope concentration ratios were 1.8 and 1.6 for 'H and "C, respectively, which suggests that a concentrating process was occurring.
Transport Characteristics of Folates in Cerebrospinal Fluid
The appearance of only MeFH*4 in CSF after the i.v. administration of either FA* or f*FH*4 and the relative delay of appearance of radioactivity in the CSF after these compounds (compared with that of Me*FH*4) suggest that the transport mechanism is specific for MeFH4 and that time is required for the metabolic conversion of these compounds to the biologically prevalent one. The demonstration that acute doses of DPH inhibit the uptake of FA* into the CSF (16) (Table I ) may depict equilibration in extracellular fluid followed by cellular uptake and metabolism, respectively. This is suggested by the relative constancy of the ti for all four compounds in phase A in contradistinction to the divergent values for phase B; these may reflect differing rates of cellular metabolism and uptake of the various compounds. Definition of the two phases was most distinct after FA*, which is consistent with the extensive metabolism this compound undergoes in its conversion to MeFH*4. That MTX* has the most rapid serum disappearance in phase B can be explained neither by rapid conversion to MeFH4, avid uptake into the CSF, nor by excessively (Table II) . It is suggested that rapid binding to dihydrofolate reductase, presumably in liver and kidney (17) , accounts for this observation. The much earlier appearance of 14C than tritium in the CSF after f*FH*4 indicates that its 1-carbon moiety is donated before CSF uptake. This early appearing 14C is probably identical with the chromatographically early appearing 14C peak (Fig. 4) and may represent incorporation of the 14C formyl group into serine or methionine. The more extensive metabolic interconversion required after FA* administration may have been too slow to allow achievement of CSF: serum equilibration during the observation period. MTX was least well taken up into the CSF, as expected from previous studies. Some interesting information concerning the interaction of DPH and MeFH4 at the transport level was obtained from this series of studies. The uptake of Mle*FH*4 into CSF was normal in dogs pretreated with DPH. Combined with the unchanged serum MeFH4 disappearance curves, these observations suggest that the transport of MeFH4 was unaffected, but they are also compatible with a series of mutually compensating and, therefore, unobserved changes. The significance of this finding has been discussed above in relation to the demonstration of inhibition of FA* uptake into the CSF by DPH (16) .
However, after intracisternal administration of Me*FH*4, the data suggested that higher serum levels were achieved after DPH pretreatment than in control animals (Fig. 3) . Inconsistencies in the rate of appearance of radioactivity in the serums of the replicate pairs may have been due to technical difficulties, such as intravascular leakage of the injected material around the intracisternal needle, or to individual differences in the rate of CSF circulation, which is known to be slow and sluggish (18) . Urinary excretion of radioactivity was lower in DPH-pretreated animals whether the route of Me*FH*4 administration was i.v. or intracisternal. That the difference in urinary excretion between control and DPH-treated animals was more marked when Me*FH*4 injection was intracisternal suggests that fo- (19) (20) (21) . In all of these, neurologic deficiency was associated with megaloblastic anemia. Luhby, Eagle, Roth, and Cooperman (19, 20) reported the case of a female infant with intestinal folate malabsorption, and megaloblastic anemia which responded to folate therapy and severe mental retardation which, however, did not improve. Strachan and Henderson (21) reported two patients with folate deficiency, megaloblastic anemia, and severe dementia. Both the hematologic and neurologic defects resolved after folic acid therapy.
That specificity is involved in the CSF transport of FA and the congeners studied has been demonstrated. It is tempting to implicate an active cellular process in the performance of this function, particularly in view of the putative relationship between neuropsychiatric function and folate metabolism as well as the folate-concentrating activity of CSF (4) and the folate-retaining capacity of brain tissue (6) . A number of selectively concentrative functions including one for MTX (22) , have been demonstrated to reside in the choroid plexus (23, 24) . On the other hand, the more rapid uptake of intravenously administered D20 by cerebral tissue than CSF (18) suggests that the selective function may reside in the endothelial cells of the cerebral microcirculation and that events occurring in the CSF may provide only a distant reflection of the vital process. The known sluggish circulation of the CSF (18) detracts from its possible role as a primary mediator in cerebral metabolism; however, the demonstration that numerous substances such as ascorbic acid (18) , penetrate cortical slices of cerebral tissue from spinal fluid reinforce the possibility of its importance.
The relative lipid solubility of substances has been suggested as a factor which determines their distribution Transport Characteristics of Folates in Cerebrospinal Fluid in neural tissue (18) , and this must be considered either as a primary mechanism or an additional factor to the cellular mechanisms discussed above. In studying a number of intravenously administered drugs, Brodie and Hogben (25) , demonstrated an inverse relationship between the time required to achieve a CSF: plasma concentration ratio of unity and the chloroform: water partition coefficient of these drugs. That such a mechanism does not apply to the CSF uptake of folates is implied by the chloroform insolubility of FA, fFH4, and MeFH4. ' The present studies which demonstrate that MeFH4 is preferentially taken up into the CSF prompt further studies of folate metabolism in the central nervous system.
